Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Camille L. Bedrosian Sells 12,425 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille L. Bedrosian sold 12,425 shares of the business’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $3.47, for a total value of $43,114.75. Following the transaction, the insider now directly owns 194,375 shares in the company, valued at approximately $674,481.25. This trade represents a 6.01 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amylyx Pharmaceuticals Trading Down 2.3 %

Shares of NASDAQ AMLX opened at $3.43 on Friday. The business’s 50 day moving average is $3.55 and its 200-day moving average is $4.05. The firm has a market cap of $303.90 million, a P/E ratio of -0.90 and a beta of -0.51. Amylyx Pharmaceuticals, Inc. has a 1-year low of $1.58 and a 1-year high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The firm had revenue of ($0.67) million during the quarter. Analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Amylyx Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $7.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in AMLX. Bank of America Corp DE raised its position in shares of Amylyx Pharmaceuticals by 165.9% in the fourth quarter. Bank of America Corp DE now owns 2,426,263 shares of the company’s stock valued at $9,171,000 after buying an additional 1,513,748 shares in the last quarter. Almitas Capital LLC raised its holdings in Amylyx Pharmaceuticals by 2.2% in the 4th quarter. Almitas Capital LLC now owns 2,032,370 shares of the company’s stock valued at $7,682,000 after acquiring an additional 43,807 shares in the last quarter. Boxer Capital Management LLC bought a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at $6,615,000. Nantahala Capital Management LLC grew its holdings in shares of Amylyx Pharmaceuticals by 3.4% during the 4th quarter. Nantahala Capital Management LLC now owns 1,452,153 shares of the company’s stock worth $5,489,000 after purchasing an additional 47,589 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Amylyx Pharmaceuticals by 43.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,263,353 shares of the company’s stock worth $4,775,000 after purchasing an additional 382,608 shares during the period. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.